


 Cite this: *RSC Adv.*, 2020, 10, 42983

Folic acid-sulfonamide conjugates as antibacterial agents: design, synthesis and molecular docking studies†

 Shabnam Shahzad,^a Muhammad Abdul Qadir,^a Mahmood Ahmed,^b Saghir Ahmad,^a Muhammad Jadoon Khan,^c Asad Gulzar^d and Muhammad Muddassar^{*c}

Dihydrofolate reductase (DHFR) inhibitors, as antibacterial agents, contain pyrimidine, pteridine, and azine moieties among many other scaffolds. Folic acid (FA), with a pteridine ring and amine group, was used as our focus scaffold, which was then conjugated with sulfonamides to develop new conjugates. The novel synthesized conjugates were characterized using infrared spectroscopy, and ¹H and ¹³C nuclear magnetic resonance (NMR) spectral studies and consequently screened for antimicrobial activities against bacterial strains with ampicillin as a positive control. Compound DS2 has the highest zone of inhibition (36.6 mm) with a percentage activity index (%AI) value of 122.8% against *S. aureus* and a minimum inhibitory concentration (MIC) of 15.63 μg mL⁻¹. DHFR enzyme inhibition was also evaluated using the synthesized conjugates through *in vitro* studies, and inhibition assays revealed that compound DS2 exhibited a 75.4 ± 0.12% (mean ± standard error of the mean (SEM)) inhibition, which is comparable with the standard DHFR inhibitor trimethoprim (74.6 ± 0.09%). The compounds attached to the unsubstituted aryl moiety of the sulfonamides revealed better inhibition against the bacterial strains as compared to the methyl substituted aryl sulfonamides. Molecular docking studies of the novel synthesized conjugates were also performed on the DHFR enzyme to identify the plausible binding modes to explore the binding mechanisms of these conjugates.

 Received 23rd October 2020
 Accepted 9th November 2020

DOI: 10.1039/d0ra09051d

rsc.li/rsc-advances

1. Introduction

The development of resistance by microorganisms to most of the existing antimicrobial drugs is a global health problem. To overcome this problem, there is an increasing need to synthesize novel antimicrobial drugs. Bacteria have the capability to adapt according to the environment of the antibacterial agent using mutations, genetic mechanisms, or selection. These multi drug resistant bacteria (MDR) cause a multitude of infections, which have aroused the need for novel antibiotics.¹ Among the Gram negative class are *Pseudomonas aeruginosa* and *Escherichia coli*, whereas Gram positive bacteria including *Proteus mirabilis* and *Staphylococcus aureus* have evolved aggressively into nosocomial pathogens that can cause severe infections such as endocarditis, meningitis, bacteremia, and infections of the biliary system, urinary tracts and

wounds. Different strategies are used to target the defense mechanisms of microorganisms and enzyme inhibition studies have evolved as a real solution to this problem. Dihydrofolate reductase (DHFR) enzyme inhibitors are potent against diverse bacteria and tumors. DHFR is significantly conserved in all domains, however, it is divergent in amino acid sequences, offering an opportunity for the selectivity of drugs to various organisms. Therefore, antifolate drugs showed success against parasitic and bacterial infections, as well as chemotherapy.²⁻⁴

Sulfonamides are curative drugs used against infections caused by microbes. The significance of sulfa drugs can never be neglected in the pharmaceutical and agricultural fields. They have stimulated researchers to design novel drugs with a lower toxicity and cost and a significant activity profile. These are structurally similar to *p*-aminobenzoic acid (PABA), so as an analog of PABA, sulfonamides can compete with it efficiently to prevent the synthesis of proteins and nucleic acid which results in the inhibition of various microorganisms.⁵⁻⁸ Moreover, a sulfonamide is a versatile moiety owing to its diverse pharmacological activities from antimicrobial to anticancer activities⁹⁻¹⁶ and its enzyme inhibition, such as cyclooxygenase, carbonic anhydrase, urease, acetylcholinesterase, butyrylcholinesterase, dihydropteroate synthase and DHFR.¹⁷⁻²⁵ Sulfonamides play a vital role as antibiotics, anti-malarial agents, protease

^aInstitute of Chemistry, University of the Punjab, Lahore-54590, Pakistan

^bRenacon Pharma Limited, Lahore-54600, Pakistan. E-mail: mahmoodresearchscholar@gmail.com

^cDepartment of Biosciences, COMSATS University Islamabad, Park Road, Islamabad, Pakistan. E-mail: mmuddassar@comsats.edu.pk

^dDivision of Science and Technology, University of Education, Lahore, Pakistan

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0ra09051d



inhibitors, antiretroviral agents in the treatment of HIV/AIDS, and for treating asthma, leukemia and epilepsy.^{26–32} To improve the activity of DHFR inhibitors, two strategies can play a vital role; improving the selectivity and potency of inhibitors through structure based design, and enhancing the permeability and solubility. Compounds containing pyrimidine, pteridine and azine moieties have already been reported as good DHFR inhibitors.^{33,34} The rate of folate metabolism accelerates during microbial infection owing to their particular DNA and for protein synthesis to maintain proper cell replication. Taking advantage of this accelerated rate of metabolism, folic acid antagonists have been used to treat various microbial infections.³⁵ As folic acid (FA) has a pteridine ring and amine group, its conjugation with a sulfonyl group forms a scaffold containing both pteridine and sulfonamide, which confer better antibacterial activities to target the anti-folate pathway.³⁶ The structural similarity of the conjugates under investigation with reported DHFR inhibitors can offer similar/better antibacterial activities and might suppress the resistance mechanism of microorganisms.^{37,38} These findings motivated us to develop novel conjugates by combining different pharmacophores into one structure with the aim of obtaining novel compounds that have significant biological activity.

2. Experimental


2.1. Chemistry

In this research, high purity chemicals were used that were acquired from Falcon Scientific, Lahore-Pakistan or Merck


(Germany), and high purity water was produced in our own lab using a Milli-Q® water system (UK). Spectral studies including Fourier-transform infrared spectroscopy (FTIR) (FTIR spectrophotometer, Agilent Technologies, Carry 630), ¹HNMR-500 MHz, ¹³CNMR-125 MHz (NMR spectrometer, Bruker, USA) and elemental analysis (C, H, N and S using a Flash elemental analyzer, HT+ Thermo Scientific, UK) were performed to elucidate the structure of the novel synthesized compounds. The melting points were determined using Gallenkamp apparatus and a PG-T80 UV-Vis spectrophotometer (PG, Instruments-UK) was used to calculate the λ_{\max} . Pre-coated silica plates (Merck, Germany) were spotted for thin layer chromatography (TLC) analysis and spots were detected under UV light to confirm the purity of the synthesized compounds.

2.2. Protocol for sulfonamide synthesis

A convenient route under dynamic pH control in an aqueous medium was used for the synthesis of the sulfonamides.^{39,40} For mono substituted (MS1–MS3) folic acid sulfonamides (Scheme 1), in a 100 mL round-bottom flask, 1 mmol folic acid was dissolved in water/dimethylformamide (DMF). Then, 1 mmol each of *p*-toluenesulfonyl chloride, benzenesulfonyl chloride and 2,4-dibromo benzenesulfonyl chloride were weighed separately and poured into the above described mixture containing folic acid (1 mmol). The pH of the reaction was maintained at 6–8 by adding 0.05 M Na₂CO₃ drop-wise and the pH was monitored using a digital pH meter (WTW, Germany). The synthesis was performed in a round-bottom flask furnished with



Scheme 1 Synthesis of monosubstituted folic acid sulfonamides.



Scheme 2 Synthesis of disubstituted folic acid sulfonamides.




a magnetic stirrer at room temperature. The progress of the reaction was determined by the drop in pH owing to the HCl formation during the reaction. Hydrogen was easily removed owing to the aqueous basic medium. After the pH had been stabilized, the solvent was evaporated in a water bath to obtain the residues. Solvent (acetone) was used to dissolve the residues and filtration was performed using a filter paper (Whatman no. 42). The acetone in the filtrate was evaporated to obtain pure crystals of the products. Crystals were then washed several times and allowed to dry. Water soluble crystals were obtained. The formation of products was confirmed by TLC on pre-coated silica TLC plates. The mobile phase used was of dichloromethane, methanol and ammonia (70 : 25 : 5) and spots were located in UV light. For di-substituted folic acid sulfonamides (Scheme 2), **MS1–MS3** were reacted by following the procedure as explained above with *p*-toluenesulfonyl chloride, benzenesulfonyl chloride and 2,4-dibromo benzenesulfonyl chloride. For trisubstituted folic acid sulfonamides (Scheme 3), **DS1–DS6** were reacted with *p*-toluenesulfonyl chloride, benzenesulfonyl chloride and 2,4-dibromo benzenesulfonyl chloride by following the above described procedure. The detailed synthesis of the folic acid linked sulfonamides with physicochemical and spectral data is explained below.

2.2.1. 2-{4-[(2-Benzenesulfonylamino-4-oxo-3,4-dihydropteridin-6-ylmethyl)-amino]-benzoylamino}-pentanedioic acid (MS1). Yellow solid; yield, 77%; mp, 255–257 °C; R_f , 0.72; IR (ATR, ν cm^{-1}): 3322, 3100, 3550 (N–H), 3419 (OH), 3085 (CH-aromatic), 1700 (C=O), 1610 (imine –CH=N–), 1484 (COOH), 1298 (–SO₂–NH₂-*asym*), 1186 (–SO₂–NH₂-*sym*), 1086 (–S=O). UV λ_{max} (nm): 285 nm. ¹H NMR (500 MHz, DMSO-*d*₆): δ_{H} 11.05 (2H, s, 2 × OH), 8.95 (1H, s, –CH=NH), 8.32 (1H, s, –NH–CO–), 8.02 (1H, s, –NH–CO-*aryl*), 7.56–7.84, (7H, m, ArH), 6.68 (2H, d, J = 7.6 Hz, ArH), 4.55 (H, t, J = 7.8 Hz, –CH), 4.35 (2H, s, –CH₂NH–), 4.29 (1H, s, –NH–CH), 2.35 (2H, t, J = 7.1 Hz, –CH₂), 2.09 (2H, t, J = 7.6 Hz, –CH₂–). ¹³C NMR (125 MHz, DMSO-*d*₆): 177.7, 174.7, 166.7, 164.2, 153.4, 151.3, 150.1, 133.7, 132.7, 130.7, 130.7, 128.9, 115.5, 115.2, 114.1, 55.2, 42.4, 34.9, 28.9. Anal. calc. for C₂₅H₂₃N₇O₈S (FW = 581.1 g mol⁻¹): C, 51.63; H, 3.99; N, 16.86; S, 5.51%. Found: C, 51.54; H, 3.88; N, 16.74; S, 5.59%.

2.2.2. 2-{4-(((2-(4-Methylphenylsulfonamido)-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido}pentanedioic acid (MS2). Yellow solid; yield, 77.0%; mp, 238–240 °C; R_f , 0.71; IR (ATR, ν cm^{-1}): 3321, 3100, 3550 (N–H), 3419 (OH), 3085 (CH-aromatic), 1700 (C=O), 1648 (imine –CH=N–), 1484 (COOH), 1298 (–SO₂–NH₂-*asym*), 1186 (–SO₂–NH₂-*sym*), 1086 (–S=O). UV λ_{max} (nm): 275 nm. ¹H NMR (500 MHz, DMSO-*d*₆): δ_{H} 11.05 (2H, s, 2 × OH), 8.95 (1H, s, –CH=N), 8.32 (1H, s, –NH–CO–), 8.02 (1H, s, –NH–CO-*aryl*), 7.67–7.84, (7H, m, ArH), 6.68 (2H, d, J = 7.6 Hz, ArH), 4.51 (H, t, J = 7.8 Hz, –CH), 4.35 (2H, s, –CH₂NH–), 4.29 (1H, s, –NH–CH), 2.34 (3H, t, J = 7.1 Hz, –CH₃), 2.07 (2H, t, J = 7.6 Hz, –CH₂–). ¹³C NMR (125 MHz, DMSO-*d*₆): 177.7, 174.7, 166.7, 164.2, 153.4, 151.3, 150.1, 133.7, 132.7, 130.7, 130.7, 128.9, 115.5, 115.2, 114.1, 55.2, 42.4, 34.9, 28.9, 21.1. Anal. calc. for C₂₆H₂₅N₇O₈S (FW = 595.1 g mol⁻¹): C, 52.43; H, 4.23; N, 16.46; S, 5.38%. Found: C, 52.59; H, 4.38; N, 16.64; S, 5.49%.

2.2.3. 2-{4-[[2-(2,4-Dibromo-benzenesulfonylamino)-4-oxo-3,4-dihydro-pteridin-6-ylmethyl]-amino]-benzoylamino}-pentanedioic acid (MS3). Brown solid; yield, 71.0%; mp, 240–242 °C; R_f , 0.72; IR (ATR, ν cm^{-1}): 3318, 3100, 3550 (N–H), 3418 (OH), 3065 (CH-aromatic), 1677 (C=O), 1600 (imine –CH=N–), 1451 (COOH), 1306 (–SO₂–NH₂-*asym*), 1173 (–SO₂–NH₂-*sym*), 1093 (–S=O). UV λ_{max} (nm): 255 nm. ¹H NMR (500 MHz, DMSO-*d*₆): δ_{H} 11.05 (2H, s, 2 × OH), 8.95 (1H, s, –CH=N), 8.43 (H, s, =CH–CH–Br), 8.33 (1H, s, –NH–CO–), 8.03 (1H, s, –NH–CO-*aryl*), 7.56–7.84, (7H, m, ArH), 6.68 (2H, d, J = 7.6 Hz, ArH), 4.51 (H, t, J = 7.8 Hz, –CH), 4.35 (2H, s, –CH₂NH–), 4.29 (1H, s, –NH–CH), 2.36 (2H, t, J = 7.1 Hz, –CH₂), 2.09 (2H, t, J = 7.6 Hz, –CH₂–). ¹³C NMR (125 MHz, DMSO-*d*₆): 177.7, 174.7, 166.7, 164.2, 153.4, 151.3, 150.1, 133.7, 132.7, 130.7, 130.7, 128.9, 115.5, 115.2, 114.1, 56.2, 42.4, 34.9, 28.9. Anal. calc. for C₂₅H₂₁Br₂N₇O₈S (FW = 738.9 g mol⁻¹): C, 40.61; H, 2.86; N, 13.26; S, 4.34%. Found: C, 40.41; H, 2.29; N, 13.37; S, 4.45%.

2.2.4. 2-(Benzenesulfonyl-{4-[[2-benzenesulfonylamino-4-oxo-3,4-dihydro-pteridin-6-ylmethyl)-amino]-benzoyl}-amino)-pentanedioic acid (DS1). Brown solid; yield, 70.0%; mp, 230–232 °C; R_f , 0.70; IR (ATR, ν cm^{-1}): 3320, 3100, 3550 (N–H), 3419 (OH), 3085 (CH-aromatic), 1687 (C=O), 1601 (imine –CH=N–), 1450 (COOH), 1298 (–SO₂–NH₂-*asym*), 1186 (–SO₂–NH₂-*sym*), 1060 (–S=O). UV λ_{max} (nm): 280 nm. ¹H NMR (500 MHz, DMSO-*d*₆):



Scheme 3 Synthesis of trisubstituted folic acid sulfonamides.



δ_{H} 11.05 (2H, s, 2 × OH), 8.99 (1H, s, -CH=N), 8.03 (1H, s, -NH-CO-aryl), 7.66–7.86, (12H, m, ArH), 6.68 (2H, d, $J = 7.6$ Hz, ArH), 4.51 (H, t, $J = 7.8$ Hz, -CH), 4.55 (2H, s, -CH₂NH-), 4.32 (1H, t, $J = 7.1$ Hz, -N-CH), 2.35 (2H, t, $J = 7.1$ Hz, -CH₂), 2.09 (2H, t, $J = 7.6$ Hz, -CH₂-). ¹³C NMR (125 MHz, DMSO-*d*₆): 177.8, 166.8, 164.7, 162.9, 153.5, 151.3, 150.1, 133.3, 130.7, 130.6, 129.4, 128.9, 115.6, 115.7, 55.6, 49.4, 35.0, 34.7, 21.5. Anal. calc. for C₃₁H₂₇N₇O₁₀S₂ (FW = 721.1 g mol⁻¹): C, 51.59; H, 3.77; N, 13.59; S, 8.89%. Found: C, 51.41; H, 3.49; N, 13.47; S, 8.65%.

2.2.5. 2-[[4-[(2-Benzenesulfonylamino-4-oxo-3,4-dihydro-pteridin-6-ylmethyl)-amino]-benzoyl]-toluene-4-sulfonyl]-amino]-pentanedioic acid (DS2). Brown solid; yield, 73.0%; mp, 280–282 °C; R_{f} , 0.73; IR (ATR, ν cm⁻¹): 3323, 3100, 3550 (N-H), 3429 (OH), 3075 (CH-aromatic), 1687 (C=O), 1601 (imine -CH=N-), 1455 (COOH), 1298 (-SO₂-NH₂-*asym*), 1160 (-SO₂-NH₂-*sym*), 1045 (-S=O). UV λ_{max} (nm): 295 nm. ¹H NMR (500 MHz, DMSO-*d*₆): δ_{H} 11.05 (2H, s, 2 × OH), 8.98 (1H, s, -CH=N), 8.02 (1H, s, -NH-CO-aryl), 7.66–7.89, (12H, m, ArH), 6.68 (2H, d, $J = 7.6$ Hz, ArH), 4.51 (H, t, $J = 7.8$ Hz, -CH), 4.54 (2H, s, -CH₂NH-), 4.33 (1H, t, $J = 7.1$ Hz, -N-CH), 2.34 (3H, t, $J = 7.1$ Hz, -CH₃), 2.07 (2H, t, $J = 7.6$ Hz, -CH₂-). ¹³C NMR (125 MHz, DMSO-*d*₆): 177.8, 166.8, 164.7, 162.9, 153.5, 151.3, 150.1, 133.3, 130.7, 130.6, 129.4, 128.9, 115.6, 115.7, 55.6, 49.4, 35.0, 34.7, 23.4, 21.5. Anal. calc. for C₃₁H₂₇N₇O₁₀S₂ (FW = 735.1 g mol⁻¹): C, 52.24; H, 3.97; N, 13.33; S, 8.72%. Found: C, 52.41; H, 3.89; N, 13.49; S, 8.85%.

2.2.6. 2-[[Benzenesulfonyl-(4-[[4-oxo-2-(toluene-4-sulfonylamino)-3,4-dihydro-pteridin-6-ylmethyl]-amino]-benzoyl)-amino]-pentanedioic acid (DS3). Brown solid; yield, 69.0%; mp, 275–277 °C; R_{f} , 0.70; IR (ATR, ν cm⁻¹): 3324, 3100, 3550 (N-H), 3418 (OH), 3065 (CH-aromatic), 1677 (C=O), 1600 (imine -CH=N-), 1451 (COOH), 1288 (-SO₂-NH₂-*asym*), 1158 (-SO₂-NH₂-*sym*), 1005 (-S=O). UV λ_{max} (nm): 290 nm. ¹H NMR (500 MHz, DMSO-*d*₆): δ_{H} 11.05 (2H, s, 2 × OH), 8.98 (1H, s, -CH=N), 8.02 (1H, s, -NH-CO-aryl), 7.66–7.89, (12H, m, ArH), 6.68 (2H, d, $J = 7.6$ Hz, ArH), 4.55 (H, t, $J = 7.8$ Hz, -CH), 4.34 (1H, t, $J = 7.1$ Hz, -N-CH), 2.35 (3H, t, $J = 7.1$ Hz, -CH₃), 2.09 (2H, t, $J = 7.6$ Hz, -CH₂-). ¹³C NMR (125 MHz, DMSO-*d*₆): 177.7, 166.8, 164.7, 162.9, 153.5, 151.3, 150.1, 133.3, 130.7, 130.6, 129.4, 128.9, 115.6, 115.7, 55.6, 49.4, 35.0, 34.7, 23.4, 21.5. Anal. calc. for C₃₁H₂₇N₇O₁₀S₂ (FW = 735.1 g mol⁻¹): C, 52.24; H, 3.97; N, 13.33; S, 8.72%. Found: C, 52.41; H, 3.89; N, 13.49; S, 8.85%.

2.2.7. 2-[[4-[[4-Oxo-2-(toluene-4-sulfonylamino)-3,4-dihydro-pteridin-6-ylmethyl]-amino]-benzoyl]-toluene-4-sulfonyl]-amino]-pentanedioic acid (DS4). Brown solid; yield, 75.0%; mp, 235–237 °C; R_{f} , 0.73; IR (ATR, ν cm⁻¹): 3328, 3100, 3550 (N-H), 3418 (OH), 3065 (CH-aromatic), 1677 (C=O), 1600 (imine -CH=N-), 1451 (COOH), 1288 (-SO₂-NH₂-*asym*), 1158 (-SO₂-NH₂-*sym*), 1001 (-S=O). UV λ_{max} (nm): 275 nm. ¹H NMR (500 MHz, DMSO-*d*₆): δ_{H} 11.05 (2H, s, 2 × OH), 8.98 (1H, s, -CH=N), 8.33 (1H, s, -NH-CO-aryl), 7.73 (4H, d, $J = 7.6$ Hz, ArH), 7.54 (4H, d, $J = 7.4$ Hz, ArH), 7.34 (4H, d, $J = 7.6$ Hz, ArH), 6.68 (2H, d, $J = 7.6$ Hz, ArH), 4.55 (2H, s, -CH₂NH-), 4.34 (1H, t, $J = 7.1$ Hz, -N-CH), 2.35 (6H, t, $J = 7.1$ Hz, 2 × CH₃), 2.33 (2H, t, $J = 7.1$ Hz, -CH₂), 2.09 (2H, t, $J = 7.6$ Hz, -CH₂-). ¹³C NMR (125 MHz, DMSO-*d*₆): 177.7, 166.8, 164.7, 162.9, 153.5, 151.3, 150.1, 133.3,

130.7, 130.6, 129.4, 128.9, 115.6, 115.7, 59.5, 49.4, 35.0, 34.7, 23.4, 21.5. C₃₃H₃₁N₇O₁₀S₂ (FW = 749.1 g mol⁻¹): C, 52.86; H, 4.17; N, 13.08; S, 8.55%. Found: C, 52.71; H, 4.09; N, 13.25; S, 8.65%.

2.2.8. 2-[[Benzenesulfonyl-(4-[[2-(2,4-dibromo-benzenesulfonylamino)-4-oxo-3,4-dihydro-pteridin-6-ylmethyl]-amino]-benzoyl)-amino]-pentanedioic acid (DS5). Brown solid; yield, 70.0%; mp, 275–277 °C; R_{f} , 0.72; IR (ATR, ν cm⁻¹): 3321, 3100, 3550 (N-H), 3418 (OH), 3085 (CH-aromatic), 1677 (C=O), 1600 (imine -CH=N-), 1451 (COOH), 1288 (-SO₂-NH₂-*asym*), 1176 (-SO₂-NH₂-*sym*), 1058 (-S=O). UV λ_{max} (nm): 240 nm. ¹H NMR (500 MHz, DMSO-*d*₆): δ_{H} 11.05 (2H, s, 2 × OH), 8.96 (1H, s, -CH=N), 8.43 (H, s, =CH-CH-Br), 8.03 (1H, s, -NH-CO-aryl), 7.56–7.84, (11H, m, ArH), 6.68 (2H, d, $J = 7.6$ Hz, ArH), 4.55 (H, t, $J = 7.8$ Hz, -CH), 4.33 (2H, s, -CH₂NH-), 4.33 (1H, t, $J = 7.1$ Hz, -N-CH), 2.35 (2H, t, $J = 7.1$ Hz, -CH₂), 2.09 (2H, t, $J = 7.6$ Hz, -CH₂-). ¹³C NMR (125 MHz, DMSO-*d*₆): 178.8, 165.8, 164.7, 162.9, 153.5, 151.3, 150.1, 133.3, 130.7, 130.6, 129.4, 128.9, 115.6, 115.7, 59.5, 49.4, 35.0, 34.7, 23.4, 21.5. Anal. calc. for C₃₁H₂₅Br₂N₇O₁₀S₂ (FW = 878.9 g mol⁻¹): C, 42.33; H, 2.87; N, 11.15; S, 7.29%. Found: C, 42.41; H, 2.79; N, 11.27; S, 7.45%.

2.2.9. 2-[[4-[[2-(2,4-Dibromo-benzenesulfonylamino)-4-oxo-3,4-dihydro-pteridin-6-ylmethyl]-amino]-benzoyl]-toluene-4-sulfonyl]-amino]-pentanedioic acid (DS6). Brown solid; yield, 72.0%; mp, 282–284 °C; R_{f} , 0.72; IR (ATR, ν cm⁻¹): 3321, 3100, 3550 (N-H), 3418 (OH), 3085 (CH-aromatic), 1677 (C=O), 1600 (imine -CH=N-), 1451 (COOH), 1288 (-SO₂-NH₂-*asym*), 1176 (-SO₂-NH₂-*sym*), 1062 (-S=O). UV λ_{max} (nm): 245 nm. ¹H NMR (500 MHz, DMSO-*d*₆): δ_{H} 11.05 (2H, s, 2 × OH), 8.96 (1H, s, -CH=N), 8.43 (H, s, =CH-CH-Br), 8.03 (1H, s, -NH-CO-aryl), 7.56–7.84, (10H, m, ArH), 6.68 (2H, d, $J = 7.6$ Hz, ArH), 4.55 (H, t, $J = 7.8$ Hz, -CH), 4.33 (2H, s, -CH₂NH-), 4.33 (1H, t, $J = 7.1$ Hz, -N-CH), 2.35 (3H, t, $J = 7.1$ Hz, -CH₃), 2.35 (2H, t, $J = 7.1$ Hz, -CH₂), 2.09 (2H, t, $J = 7.6$ Hz, -CH₂-). ¹³C NMR (125 MHz, DMSO-*d*₆): 178.8, 165.8, 164.7, 162.9, 153.5, 151.3, 150.1, 133.3, 130.7, 130.6, 129.4, 128.9, 115.6, 115.7, 59.5, 49.4, 30.4, 23.4, 21.5. Anal. calc. for C₃₂H₂₇Br₂N₇O₁₀S₂ (FW = 892.9 g mol⁻¹): C, 43.01; H, 3.05; N, 10.97; S, 7.18%. Found: C, 42.91; H, 3.09; N, 11.17; S, 7.05%.

2.2.10. 2-(Benzenesulfonyl-(4-[[benzenesulfonyl-(2-benzenesulfonylamino-4-oxo-3,4-dihydro-pteridin-6-ylmethyl)-amino]-benzoyl)-amino)-pentanedioic acid (TS1). Yellowish brown solid; yield, 75.0%; mp, 265–267 °C; R_{f} , 0.71; IR (ATR, ν cm⁻¹): 3320, 3100, 3550 (N-H), 3416 (OH), 3055 (CH-aromatic), 1667 (C=O), 1606 (imine -CH=N-), 1450 (COOH), 1284 (-SO₂-NH₂-*asym*), 1166 (-SO₂-NH₂-*sym*), 1045 (-S=O). UV λ_{max} (nm): 295 nm. ¹H NMR (500 MHz, DMSO-*d*₆): δ_{H} 11.1 (2H, s, 2 × OH), 8.99 (1H, s, -CH=N), 8.42 (1H, s, -NH-CO-aryl), 6.88–7.46, (17H, m, ArH), 6.86 (2H, d, $J = 7.6$ Hz, ArH), 4.45 (H, t, $J = 7.8$ Hz, -CH), 4.45 (2H, s, -CH₂N-), 4.28 (1H, t, $J = 7.1$ Hz, -N-CH), 2.44 (2H, t, $J = 7.1$ Hz, -CH₂), 2.09 (2H, t, $J = 7.6$ Hz, -CH₂-). ¹³C NMR (125 MHz, DMSO-*d*₆): 178.7, 163.5, 161.5, 155.2, 138.9, 131.8, 130.1, 129.8, 128.6, 127.9, 124.9, 120.3, 117.7, 52.4, 49.6, 36.9, 29.9, 28.3, 26.6, 22.0. Anal. calc. for C₃₇H₃₁N₇O₁₂S₃ (FW = 861.1 g mol⁻¹): C, 51.56; H, 3.63; N, 11.38; S, 11.16%. Found: C, 51.41; H, 3.49; N, 11.47; S, 11.25%.

2.2.11. 2-[[4-[[2-(Benzenesulfonylamino-4-oxo-3,4-dihydro-pteridin-6-ylmethyl)-toluene-4-sulfonyl]-amino]-benzoyl]-toluene-4-sulfonyl]-amino]-pentanedioic acid (TS2). Brown



solid; yield, 75.0%; mp, 275–277 °C; R_f , 0.71; IR (ATR, ν cm⁻¹): 3319, 3100, 3550 (N–H), 3418 (OH), 3065 (CH-aromatic), 1677 (C=O), 1606 (imine –CH=N–), 1450 (COOH), 1288 (–SO₂–NH₂-*asym*), 1158 (–SO₂–NH₂-*sym*), 1045 (–S=O). UV λ_{max} (nm): 290 nm. ¹H NMR (500 MHz, DMSO-*d*₆): δ_H 11.1 (2H, s, 2× OH), 8.99 (1H, s, –CH=N), 8.42 (1H, s, –NH–CO-*aryl*), 6.88–7.46, (17H, m, ArH), 6.86 (2H, d, J = 7.6 Hz, ArH), 4.45 (H, t, J = 7.8 Hz, –CH), 4.45 (2H, s, –CH₂N–), 4.28 (1H, t, J = 7.1 Hz, –N–CH), 2.44 (2H, t, J = 7.1 Hz, –CH₂), 2.09 (2H, t, J = 7.6 Hz, –CH₂–). ¹³C NMR (125 MHz, DMSO-*d*₆): 178.9, 159.6, 157.2, 152.4, 143.6, 139.2, 135.4, 129.6, 129.3, 128.9, 128.1, 127.9, 52.6, 49.9, 37.2, 30.1, 28.5, 26.9, 22.2, 21.7. Anal. calc. for C₃₉H₃₅N₇O₁₂S₃ (FW = 889.1 g mol⁻¹): C, 52.64; H, 3.96; N, 11.02; S, 10.81%. Found: C, 52.41; H, 3.79; N, 11.16; S, 10.62%.

2.2.12. 2-[Benzenesulfonyl-(4-{benzenesulfonyl-[4-oxo-2-(toluene-4-sulfonylamino)-3,4-dihydro-pteridin-6-ylmethyl]-amino}-benzoyl)-amino]-pentanedioic acid (TS3). Brown solid; yield, 68.0%; mp, 292–294 °C; R_f , 0.72; IR (ATR, ν cm⁻¹): 3324, 3100, 3550 (N–H), 3418 (OH), 3065 (CH-aromatic), 1677 (C=O), 1600 (imine –CH=N–), 1451 (COOH), 1288 (–SO₂–NH₂-*asym*), 1158 (–SO₂–NH₂-*sym*), 1045 (–S=O). UV λ_{max} (nm): 295 nm. ¹H NMR (500 MHz, DMSO-*d*₆): δ_H 11.07 (2H, s, 2× OH), 8.87 (1H, s, –CH=N), 8.42 (1H, s, –NH–CO-*aryl*), 6.88–7.46, (16H, m, ArH), 6.86 (2H, d, J = 7.6 Hz, ArH), 4.45 (H, t, J = 7.8 Hz, –CH), 4.45 (2H, s, –CH₂N–), 4.28 (1H, t, J = 7.1 Hz, –N–CH), 2.44 (3H, t, J = 7.1 Hz, CH₃), 2.44 (2H, t, J = 7.1 Hz, –CH₂), 2.09 (2H, t, J = 7.6 Hz, –CH₂–). ¹³C NMR (125 MHz, DMSO-*d*₆): 178.9, 160.5, 157.2, 152.4, 143.6, 139.2, 135.4, 129.6, 129.3, 128.9, 128.1, 127.9, 52.6, 49.9, 37.2, 30.1, 28.5, 26.9, 22.2, 21.7. Anal. calc. for C₃₈H₃₃N₇O₁₂S₃ (FW = 875.1 g mol⁻¹): C, 52.11; H, 3.80; N, 11.19; S, 10.98%. Found: C, 52.32; H, 3.64; N, 11.25; S, 10.85%.

2.2.13. 2-[[4-Oxo-2-(toluene-4-sulfonylamino)-3,4-dihydro-pteridin-6-ylmethyl]-(toluene-4-sulfonyl)-amino]-benzoyl]-(toluene-4-sulfonyl)-amino]-pentanedioic acid (TS4). Brown solid; yield, 75.0%; mp, 282–284 °C; R_f , 0.71; IR (ATR, ν cm⁻¹): 3319, 3100, 3550 (N–H), 3418 (OH), 3065 (CH-aromatic), 1677 (C=O), 1606 (imine –CH=N–), 1450 (COOH), 1288 (–SO₂–NH₂-*asym*), 1158 (–SO₂–NH₂-*sym*), 1045 (–S=O). UV λ_{max} (nm): 290 nm. ¹H NMR (500 MHz, DMSO-*d*₆): δ_H 11.07 (2H, s, 2× OH), 8.87 (1H, s, –CH=N), 8.42 (1H, s, –NH–CO-*aryl*), 6.88–7.49, (16H, m, ArH), 6.86 (2H, d, J = 7.6 Hz, ArH), 4.45 (H, t, J = 7.8 Hz, –CH), 4.45 (2H, s, –CH₂N–), 4.28 (1H, t, J = 7.1 Hz, –N–CH), 2.44 (3H, t, J = 7.1 Hz, CH₃), 2.44 (2H, t, J = 7.1 Hz, –CH₂), 2.09 (2H, t, J = 7.6 Hz, –CH₂–). ¹³C NMR (125 MHz, DMSO-*d*₆): 179.7, 167.1, 163.1, 152.6, 149.5, 139.6, 139.5, 138.4, 130.8, 130.3, 129.5, 125.6, 125.2, 114.1, 55.8, 52.6, 51.5, 37.8, 30.2, 30.1, 29.9, 28.5, 26.8, 26.0 22.9, 22.5. Anal. calc. for C₄₀H₃₇N₇O₁₂S₃ (FW = 903.1 g mol⁻¹): C, 53.15; H, 4.13; N, 10.85; S, 10.64%. Found: C, 53.35; H, 4.21; N, 10.66; S, 10.71%.

2.2.14. 2-[Benzenesulfonyl-(4-{benzenesulfonyl-[2-(2,4-dibromo-benzenesulfonylamino)-4-oxo-3,4-dihydro-pteridin-6-ylmethyl]-amino}-benzoyl)-amino]-pentanedioic acid (TS5). Yellowish brown solid; yield, 71.0%; mp, 282–284 °C; R_f , 0.72; IR (ATR, ν cm⁻¹): 3324, 3100, 3550 (N–H), 3418 (OH), 3055 (CH-aromatic), 1667 (C=O), 1606 (imine –CH=N–), 1450 (COOH), 1288 (–SO₂–NH₂-*asym*), 1158 (–SO₂–NH₂-*sym*), 1045 (–S=O). UV λ_{max} (nm): 280 nm. ¹H NMR (500 MHz, DMSO-*d*₆): δ_H 11.07 (2H, s, 2× OH), 8.87 (1H, s, –CH=N), 8.67 (1H, s, =CH–CH–Br), 8.42 (1H, s,

–NH–CO-*aryl*), 6.88–7.48, (15H, m, ArH), 6.86 (2H, d, J = 7.6 Hz, ArH), 4.45 (H, t, J = 7.8 Hz, –CH), 4.45 (2H, s, –CH₂N–), 4.28 (1H, t, J = 7.1 Hz, –N–CH), 2.44 (2H, t, J = 7.1 Hz, –CH₂), 2.09 (2H, t, J = 7.6 Hz, –CH₂–). ¹³C NMR (125 MHz, DMSO-*d*₆): 179.8, 167.1, 163.1, 152.7, 149.5, 139.7, 139.5, 138.4, 130.8, 130.3, 129.5, 125.6, 125.2, 114.0, 55.8, 52.6, 51.5, 37.8, 30.2, 30.1, 29.9, 28.5, 26.8, 26.0. Anal. calc. for C₃₇H₂₉Br₂N₇O₁₂S₃ (FW = 1018.9 g mol⁻¹): C, 43.58; H, 2.87; N, 9.62; S, 9.43%. Found: C, 43.41; H, 2.79; N, 9.47; S, 9.25%.

2.2.15. 2-[[4-[[2-(2,4-Dibromo-benzenesulfonylamino)-4-oxo-3,4-dihydro-pteridin-6-ylmethyl]-(toluene-4-sulfonyl)-amino]-benzoyl]-(toluene-4-sulfonyl)-amino]-pentanedioic acid (TS6). Yellowish brown solid; yield, 69.0%; mp, 285–287 °C; R_f , 0.72; IR (ATR, ν cm⁻¹): 3321, 3100, 3550 (N–H), 3419 (OH), 3075 (CH-aromatic), 1675 (C=O), 1606 (imine –CH=N–), 1450 (COOH), 1286 (–SO₂–NH₂-*asym*), 1158 (–SO₂–NH₂-*sym*), 1045 (–S=O). UV λ_{max} (nm): 245 nm. ¹H NMR (500 MHz, DMSO-*d*₆): δ_H 11.07 (2H, s, 2× OH), 8.87 (1H, s, –CH=N), 8.67 (1H, s, =CH–CH–Br), 8.42 (1H, s, –NH–CO-*aryl*), 6.88–7.48, (15H, m, ArH), 6.86 (2H, d, J = 7.6 Hz, ArH), 4.45 (H, t, J = 7.8 Hz, –CH), 4.45 (2H, s, –CH₂N–), 4.28 (1H, t, J = 7.1 Hz, –N–CH), 2.24 (2H, t, J = 7.1 Hz, –CH₂), 2.09 (2H, t, J = 7.6 Hz, –CH₂–). ¹³C NMR (125 MHz, DMSO-*d*₆): 179.6, 167.5, 163.5, 152.6, 149.5, 139.6, 139.5, 138.7, 130.9, 130.3, 129.5, 125.6, 125.2, 114.1, 55.8, 52.6, 51.5, 37.8, 30.2, 30.2, 29.8, 28.5, 26.8, 26.0 22.9, 22.5. Anal. calc. for C₃₇H₂₉Br₂N₇O₁₂S₃ (FW = 1046.9 g mol⁻¹): C, 44.71; H, 3.17; N, 9.36; S, 9.18%. Found: C, 44.48; H, 3.29; N, 9.47; S, 9.25%.

2.3. Antibacterial activities

Disk diffusion and 96-well plate assay methods were employed to determine the zone of inhibition and the minimum inhibitory concentration (MIC) respectively, to investigate the antibacterial activities, where ampicillin was used as a reference drug as described in our previous studies,^{21,41} details of which are provided in the ESI.†

2.3.1. Percentage activity and fractional inhibitory concentration index. The percentage activity index (%AI) was determined using the formula given in eqn (A), with respect to reference drugs such as ampicillin. The fractional inhibitory concentration (FIC) index was determined by combination studies (eqn (B)). A combined FIC value of less than or equal to 0.5 was considered synergy, a value of greater than 0.5–1 indicated an additive effect of the two drugs, a value of greater than 1–4 was considered indifferent and a combined FIC value of greater than 4 was taken to suggest antagonism.^{21,42}

$$\%AI = \frac{\text{zone of inhibition of synthetic derivative}}{\text{zone of inhibition of reference drug}} \times 100 \quad (\text{A})$$

$$FIC = \frac{\text{MIC of compound A in mixture}}{\text{MIC of compound A alone}} + \frac{\text{MIC of compound B in mixture}}{\text{MIC of compound B alone}} \quad (\text{B})$$

2.3.2. Dihydrofolate reductase inhibitory activity. A dihydrofolate reductase inhibition assay was performed at 25 °C by following the decrease in absorbance of NADPH (nicotinamide



Table 1 Antibacterial data according to the zone of inhibition (mean \pm SD, $n = 3$) at three gradient concentrations for folic acid-sulfonamide conjugates

Compound	Gram (+) bacteria		Gram (-) bacteria	
	<i>S. aureus</i>	<i>P. mirabilis</i>	<i>E. coli</i>	<i>P. aeruginosa</i>
MS1	31.1 \pm 0.06, 29.9 \pm 0.06, 27.8 \pm 0.06	29.3 \pm 0.06, 27.9 \pm 0.06, 22.0 \pm 0.15	31.1 \pm 0.12, 29.8 \pm 0.06, 24.1 \pm 0.12	30.9 \pm 0.06, 28.2 \pm 0.06, 17.8 \pm 0.06
MS2	29.8 \pm 0.06, 28.8 \pm 0.11, 26.8 \pm 0.06	27.8 \pm 0.06, 24.0 \pm 0.12, 22.1 \pm 0.06	29.8 \pm 0.06, 28.9 \pm 0.10, 23.7 \pm 0.06	27.9 \pm 0.06, 25.8 \pm 0.06, 15.8 \pm 0.06
MS3	31.9 \pm 0.06, 27.9 \pm 0.06, 22.1 \pm 0.06	28.1 \pm 0.06, 24.3 \pm 0.06, 22.5 \pm 0.06	33.1 \pm 0.12, 28.4 \pm 0.06, 24.7 \pm 0.06	29.2 \pm 0.06, 27.8 \pm 0.06, 20.3 \pm 0.06
DS1	32.8 \pm 0.06, 30.9 \pm 0.06, 28.7 \pm 0.06	23.3 \pm 0.12, 29.8 \pm 0.06, 28.5 \pm 0.06	34.9 \pm 0.06, 32.3 \pm 0.06, 29.3 \pm 0.06	32.8 \pm 0.06, 31.9 \pm 0.06, 18.5 \pm 0.06
DS2	36.6 \pm 0.06, 31.5 \pm 0.06, 30.5 \pm 0.06	35.8 \pm 0.12, 30.1 \pm 0.12, 29.6 \pm 0.06	37.8 \pm 0.10, 33.3 \pm 0.06, 31.6 \pm 0.06	34.8 \pm 0.06, 32.1 \pm 0.06, 30.9 \pm 0.06
DS3	30.8 \pm 0.06, 27.8 \pm 0.06, 26.8 \pm 0.06	29.8 \pm 0.12, 23.8 \pm 0.06, 22.3 \pm 0.06	31.6 \pm 0.06, 29.3 \pm 0.06, 23.7 \pm 0.06	28.8 \pm 0.06, 27.8 \pm 0.06, 17.9 \pm 0.06
DS4	31.8 \pm 0.06, 29.1 \pm 0.06, 26.8 \pm 0.06	30.8 \pm 0.06, 28.9 \pm 0.06, 26.4 \pm 0.12	34.9 \pm 0.06, 32.4 \pm 0.10, 28.7 \pm 0.12	30.9 \pm 0.12, 29.4 \pm 0.06, 27.4 \pm 0.15
DS5	34.8 \pm 0.06, 30.8 \pm 0.06, 28.6 \pm 0.06	33.5 \pm 0.06, 29.5 \pm 0.06, 28.4 \pm 0.12	36.5 \pm 0.06, 32.3 \pm 0.06, 28.9 \pm 0.06	32.8 \pm 0.06, 31.3 \pm 0.06, 29.3 \pm 0.12
DS6	33.8 \pm 0.06, 31.7 \pm 0.06, 28.4 \pm 0.11	33.2 \pm 0.12, 29.2 \pm 0.06, 28.7 \pm 0.06	36.7 \pm 0.06, 32.4 \pm 0.06, 29.7 \pm 0.12	34.0 \pm 0.06, 31.3 \pm 0.06, 29.9 \pm 0.06
TS1	32.5 \pm 0.06, 26.5 \pm 0.06, 23.8 \pm 0.06	31.3 \pm 0.06, 29.3 \pm 0.06, 24.1 \pm 0.06	34.7 \pm 0.06, 30.8 \pm 0.06, 26.0 \pm 0.06	29.4 \pm 0.06, 27.6 \pm 0.10, 24.2 \pm 0.06
TS2	31.8 \pm 0.06, 28.8 \pm 0.06, 25.8 \pm 0.06	30.7 \pm 0.06, 27.7 \pm 0.06, 26.2 \pm 0.06	34.8 \pm 0.05, 31.9 \pm 0.05, 29.5 \pm 0.09	31.2 \pm 0.09, 29.3 \pm 0.09, 27.3 \pm 0.09
TS3	32.5 \pm 0.06, 26.8 \pm 0.06, 23.4 \pm 0.06	30.8 \pm 0.06, 29.7 \pm 0.06, 24.1 \pm 0.06	34.6 \pm 0.05, 30.1 \pm 0.09, 24.4 \pm 0.09	29.7 \pm 0.09, 27.9 \pm 0.05, 24.5 \pm 0.19
TS4	20.3 \pm 0.06, 15.8 \pm 0.06, 10.8 \pm 0.06	18.3 \pm 0.06, 14.4 \pm 0.06, 10.8 \pm 0.06	19.3 \pm 0.09, 12.1 \pm 0.09, 10.8 \pm 0.09	20.1 \pm 0.09, 17.7 \pm 0.09, 14.3 \pm 0.05
TS5	34.8 \pm 0.06, 31.7 \pm 0.06, 28.4 \pm 0.06	33.2 \pm 0.06, 29.2 \pm 0.06, 28.6 \pm 0.06	36.7 \pm 0.05, 32.4 \pm 0.08, 29.7 \pm 0.08	33.9 \pm 0.05, 31.3 \pm 0.09, 29.9 \pm 0.09
TS6	23.1 \pm 0.06, 15.3 \pm 0.06, 11.1 \pm 0.06	19.0 \pm 0.06, 14.4 \pm 0.06, 10.7 \pm 0.06	19.6 \pm 0.05, 12.4 \pm 0.09, 10.9 \pm 0.05	20.9 \pm 0.05, 17.8 \pm 0.05, 14.6 \pm 0.05
Folic acid	—, —, —	—, —, —	—, —, —	—, —, —
<i>p</i> -Toluenesulfonyl chloride	—, —, —	—, —, —	—, —, —	—, —, —
Benzenesulfonyl chloride	—, —, —	—, —, —	—, —, —	—, —, —
2,4-Dibromo benzenesulfonyl chloride	—, —, —	—, —, —	—, —, —	—, —, —
^a Ampicillin	29.8 \pm 0.06, 28.1 \pm 0.06, 26.7 \pm 0.06	30.5 \pm 0.06, 29.5 \pm 0.06, 28.2 \pm 0.06	33.6 \pm 0.12, 30.1 \pm 0.08, 29.1 \pm 0.08	29.2 \pm 0.08, 27.3 \pm 0.05, 26.2 \pm 0.08
^b Trimethoprim	28.3 \pm 0.05, 20.3 \pm 0.05, 18.3 \pm 0.09	25.0 \pm 0.09, 20.3 \pm 0.05, 14.4 \pm 0.09	31.0 \pm 0.17, 25.1 \pm 0.09, 20.1 \pm 0.08	14.2 \pm 0.05, 9.3 \pm 0.05, 4.1 \pm 0.05

^a Control drug. ^b Reference DHFR inhibitor. The zone of inhibition was measured in mm \pm SD, gradient concentrations of 3, 1.5, and 0.75 mg mL⁻¹ were used. *S. aureus* = *Staphylococcus aureus*, *E. coli* = *Escherichia coli*, *P. aeruginosa* = *Pseudomonas aeruginosa*, and *P. mirabilis* = *Proteus mirabilis*.

adenine dinucleotide phosphate) and DHF (dihydrofolate) which was measured at 340 nm, as previously described in the literature.^{4,43} Briefly, the reaction mixture contained DHFR (20 μ L, 125 ng mL⁻¹), the tested compound (40 μ L, 20 μ g mL⁻¹), DHF (5 μ L, 100 mM), NADPH (5 μ L, 100 mM), and mercaptoethanol (100 μ L, 5 mM in Hepes buffer, 100 mM at pH = 7.0). The plate was shaken for 10 s and incubated at 25 $^{\circ}$ C for 5 min. The absorbance of each well at 340 nm was noted using a micro plate reader LT-4500 (Labtech International Ltd, UK) and the DHFR inhibition (%) was calculated using the formula.

$$\%DHFR \text{ inhibition} = 1 - \frac{T}{C} \times 100$$

In which *T* is the absorbance of the inhibitory well and *C* is absorbance of 100% initial activity without inhibitor.

2.4. Molecular docking studies

2.4.1. Protein structure and ligand preparation. Crystal structures of dihydrofolate reductase (DHFR), that are available in the protein data bank, (<http://www.rcsb.org>) with PDB ID = 2W9S, co-crystallized with ligands (trimethoprim and NADPH) at a high resolution of 1.80 Å were selected for the studies.⁴⁴ The coordinates of the active site were taken from this structure. The protein for docking was prepared by “protein preparation wizard” using the Schrodinger software suite. The hetero atoms, water molecules and other cofactors were removed from the target protein and hydrogen atoms were added into the crystal structure. Restrained minimization was performed for the prepared enzyme up to 0.3 Å of the original structure employing a force field (OPLSA_2005) in order to remove steric clashes.



Prior to the docking studies, the 2D structures of the synthesized ligands were drawn and converted to energy minimized 3D structures in the Mol file format using ACD/ChemSketch (Advanced Chemistry Development, Canada). All synthesized compounds conformers were generated, and different ionization states were created using the Schrodinger LigPrep module. The standard drug molecule used in the positive control was also prepared in the same way. Pymol software was used for visualization of the docked poses of the compounds.

2.4.2. Molecular docking protocols. Before docking, a grid box was generated around the folic acid present in the active site of the enzyme. Then, molecular docking simulations of the synthetic compounds in DHFR were performed using the Glide software²⁷ implemented in Schrodinger Software Suites. Docking was performed using the SP and XP mode of the glide software. The hydrogen atoms in the active sites of amino acids were allowed to rotate throughout the simulations. No extra positional or torsional strain was applied. For each compound, the top five poses were subjected to minimization and the best pose was retained based on the highest Glide score.

3. Results and discussion

3.1. Chemistry

Conjugated sulfonamides were synthesized by the reaction of *p*-toluenesulfonyl chloride, benzenesulfonyl chloride and 2,4-dibromo benzenesulfonyl chloride with folic acid (details are explained in the Experimental section) and their biological activities were evaluated against bacterial strains such as *Proteus mirabilis* (ATCC 43071), *Pseudomonas aeruginosa* (ATCC-

27853), *Escherichia coli* (ATCC-25922) and *Staphylococcus aureus* (ATCC-25923).

The amine groups of FA can be numbered as N₁, N₂ and N₃ according to their preference of availability for electrophile attack. The reaction was carried out at basic pH (0.05 M, Na₂CO₃) because folic acid is soluble in the basic environment, as well as assisting the electrophilic attack of sulfonyl chloride. HCl was formed as a by-product that raised the pH towards an acidic value which was neutralized by the base present in the reaction mixture. Mono-substituted FA-derivatives (**MS1–MS3**, Scheme 1) were obtained by the attack of the sulfur atom at N₁, then monosubstituted derivatives were reacted with sulfonyl chlorides to obtain the disubstituted FA-derivatives (**DS1–DS6**, Scheme 2), consequently these were reacted again with the sulfonyl chlorides to obtain the trisubstituted FA-derivatives (**TS1–TS6**). The first sulfonyl chlorides attack was on N₁ as it is a primary nitrogen (–NH₂), that is, the most easily accessible, and then N₂ and N₃ as they are facing steric hindrance owing to the presence of aromatic rings in their neighborhoods. UV/Vis, FTIR, and ¹H and ¹³C NMR spectroscopic techniques were used to characterize the novel synthesized compounds.

A strong absorption band in the 1148–1153 cm⁻¹ (symmetrical) and 1315–1362 cm⁻¹ (unsymmetrical) region for the **MS1–MS3** compounds, the 1132–1170 cm⁻¹ (symmetrical) and 1345–1375 cm⁻¹ (unsymmetrical) region for the **DS1–DS6** compounds and the 1125–1162 cm⁻¹ (symmetrical) and 1344–1370 cm⁻¹ (unsymmetrical) region confirm the presence of the –NH–S=O group. Moreover, a characteristic sulfoxide absorption band appeared in the 1026–1032 cm⁻¹ region for all the synthetic compounds. The peaks for the –NH proton of the –SO₂NH–

Table 2 Antibacterial data as MIC and %AI for folic acid-sulfonamide conjugates

Compound	Gram (+) bacteria				Gram (-) bacteria			
	<i>S. aureus</i>		<i>P. mirabilis</i>		<i>E. coli</i>		<i>P. aeruginosa</i>	
	MIC	AI	MIC	AI	MIC	AI	MIC	AI
MS1	15.63	104.7	15.63	96.1	31.25	92.5	15.63	106.2
MS2	31.25	100.3	31.25	91.5	31.25	89.3	15.63	95.5
MS3	31.25	107.0	31.25	92.4	31.25	98.5	15.63	100
DS1	15.63	110.1	62.50	109.5	125.0	104.2	15.63	113.1
DS2	15.63	122.8	15.63	117.7	15.63	112.8	15.63	119.2
DS3	15.63	103.0	15.63	98.0	31.25	95.2	15.63	99.3
DS4	15.63	107.0	15.63	100.9	31.25	103.9	15.63	105.8
DS5	15.63	116.4	15.63	110.2	31.25	108.6	15.63	112.4
DS6	31.25	113.8	31.25	109.2	31.25	109.3	31.25	116.5
TS1	15.63	109.4	15.63	101.6	31.25	103.3	15.63	100.7
TS2	15.63	106.7	15.63	100.9	31.25	113.8	15.63	106.9
TS3	15.63	109.1	15.63	101.3	62.50	102.9	15.63	101.7
TS4	125.0	67.8	250.0	59.7	250.0	57.3	125.0	68.7
TS5	15.63	117.1	15.63	109.2	31.25	109.3	15.63	116.5
TS6	125.0	77.8	250.0	62.6	250.0	58.2	250.0	71.5
Folic acid	>1000	—	>1000	—	>1000	—	>1000	—
<i>p</i> -Toluenesulfonyl chloride	>1000	—	>1000	—	>1000	—	>1000	—
Benzenesulfonyl chloride	>1000	—	>1000	—	>1000	—	>1000	—
2,4-Dibromo benzenesulfonyl chloride	>1000	—	>1000	—	>1000	—	>1000	—
^a Ampicillin	125.0	100.0	125.0	100.0	15.63	100.0	125.0	100.0

^a Control drug. %AI = percentage activity index, MIC = minimum inhibitory concentrations in μg mL⁻¹.



group appeared at δ 10.47–12.43 ppm and confirmed the formation of the sulfonamides. The compounds gave a singlet at δ 2.49–2.48 ppm assigned to a proton of $-\text{CH}_3$ linked to the aryl moiety. In the ^{13}C NMR spectra, the 143–163 ppm peaks were assigned to the presence of an imine carbon ($-\text{C}=\text{N}-$) while the peaks at 165.2–179.8 ppm were assigned to the carbonyl carbon. The signals at 134.24–146.45 were assigned to the aryl carbons, as there are three types of nitrogen, and the highest value signals were at the N_3 substitution of the sulfonyl chlorides, which is bound to two aromatic rings and offered a high delocalization. Therefore, the ^{13}C NMR spectral analyses were consistent with the assigned structure of all the compounds.

3.2. Antibacterial activities

The novel synthesized derivatives were assessed as antibacterial agents. The disk diffusion method was utilized to measure the inhibition zone and MIC via the 96-well plate method by measuring the optical density (OD) at 600 nm using a two-fold serial dilution method. Four bacterial strains were used, including two from each group, Gram negative bacteria (*P. aeruginosa*, *E. coli*) and Gram positive (*S. aureus*, *P. mirabilis*). Ampicillin was used as a reference drug while trimethoprim was considered as a reference DHFR inhibitor. FA and respective sulfonyl chloride were also screened for antibacterial activity. The %AI of each synthetic compound was also measured as compared to the standard drug ampicillin. The zone of inhibition for each synthetic compound was measured in triplicate at three gradient concentrations (Tables S1 and S2, ESI†) such as 3, 1.5 and 0.75 mg mL⁻¹.

The compounds **MS3**, **DS1**, **DS2**, **DS5**, **DS6** and **TS5** have an appreciable antibacterial activity against all strains of bacteria (Tables 1 and 2). Compound **DS2** has the highest zone of inhibition (36.6 mm) with a %AI value of 122.8% against *S. aureus* and a MIC of 15.63 $\mu\text{g mL}^{-1}$. Sulfonyl chlorides did not show any response against the bacterial strains, while folic acid showed a small amount of activity for the highest concentration (3 mg mL⁻¹). The FA derivatives showed a good activity that could be attributed to the presence of a pyrimidine ring in its scaffold and the resulting sulfonamides that can cause the inhibition of dihydrofolate reductase synthesis. Owing to the interaction of FA with bacterial cell membranes, it may offer enhanced permeability inside the microbial cells. Thus, the FA moiety can be an essential nutrient for DNA/RNA synthesis in bacteria, and may assist the transportation of sulfonamides via endocytosis into the cytoplasm, easily crossing the plasma membrane.^{45,46}

From a structure activity relationship point of view of the compounds, the compounds that showed the lowest MIC and highest inhibition are a result of the presence of electron withdrawing halogens (Br) attached to the aryl ring. In contrast, the compounds with an unsubstituted aryl moiety of sulfonamides also revealed excellent inhibition against bacterial strains compared to the methyl substitution on the aryl moiety, which is an electron donating group and decreases the inhibition effect.

3.3. FIC index calculation

The combination of two or more drugs could have more of a therapeutic effective than the sum of the independent effects

Table 3 Combination effect of compound **DS2** with the antibacterial drug ampicillin^a

Bacteria	Compounds	MIC	FIC index	Effect
<i>S. aureus</i>	Ampicillin	31.25	0.75	Additive
	DS2	7.82		
<i>P. mirabilis</i>	Ampicillin	62.5	1.0	Additive
	DS2	7.82		
<i>E. coli</i>	Ampicillin	3.91	0.75	Additive
	DS2	7.82		
<i>P. aeruginosa</i>	Ampicillin	62.5	1.0	Additive
	DS2	7.82		

^a MIC = minimum inhibitory concentrations in $\mu\text{g mL}^{-1}$.

caused by the individual component, as well as the toxicity and other side effects associated with high doses of a single drug. Medication compliance could also be improved by reducing the pill burden of patients with a better efficacy and smaller side effects compared to single drugs because the development and progression of systemic diseases often involves complex biological processes.^{47–49} The FIC index, as depicted in Table 3, combines the strong acting sulfonamide **DS2** with ampicillin and revealed a broad antibacterial spectrum with a reduced dosage. Moreover, the FIC index was less than or equal to 1, which indicated that the combination system had a good additive effect. Notably, the combination of ampicillin (3.91 $\mu\text{g mL}^{-1}$) with the compound **DS2** (7.82 $\mu\text{g mL}^{-1}$) inhibited the growth of *E. coli*, which was four-fold more potent than ampicillin alone, as described in Table 3.

3.4. Dihydrofolate reductase inhibitory activity

All of the FA conjugates were tested for inhibitory activity against bovine DHFR, the percentage inhibition values were calculated in triplicate and the average inhibitory value of each compound is presented in Table 4. Trimethoprim was used as a standard

Table 4 Binding energy (ΔG) and the percentage DHFR inhibition of the synthesized compounds against DHFR

Compound	Glide score (kcal mol ⁻¹)	%DHFR inhibition at 10 $\mu\text{g mL}^{-1}$ (mean \pm SEM)
MS1	-6.4	65.5 \pm 0.12
MS2	-7.1	61.4 \pm 0.09
MS3	-6.7	62.3 \pm 0.15
DS1	-5.7	68.7 \pm 0.07
DS2	-6.7	75.4 \pm 0.12
DS3	-6.9	63.4 \pm 0.09
DS4	-7.5	64.6 \pm 0.03
DS5	-6.3	68.9 \pm 0.03
DS6	-7.2	71.5 \pm 0.09
TS1	-5.5	65.6 \pm 0.03
TS2	-5.6	69.5 \pm 0.17
TS3	-7.7	67.8 \pm 0.13
TS4	-6.2	59.6 \pm 0.07
TS5	-7.9	64.8 \pm 0.09
TS6	-4.7	58.6 \pm 0.03
^a Trimethoprim	-5.9	74.6 \pm 0.09

^a Reference DHFR inhibitor.






Fig. 1 Probable binding mode of the most active compound **DS2** in the DHFR active site. (a) Superposition of docked **DS2** (yellow) in the active site of the DHFR surface containing trimethoprim (cyan color). (b) Binding site (green sticks) containing 4A residues around the docked pose of **DS2** (yellow), the white sticks are the NADPH substrate and the dotted lines (magenta) represent hydrogen bonding. Interatomic distances are shown in Angstrom.

DHFR inhibitor. The results (mean \pm standard error of the mean (SEM)) demonstrate that compound **DS2** exhibited a $75.4 \pm 0.12\%$ inhibition, whereas the standard drug (trimethoprim as the reference DHFR inhibitor) showed a $74.6 \pm 0.09\%$ inhibition.

3.5. Molecular docking studies

Different sulfonamide containing compounds and folic acid derivatives inhibit the biological function of the DHFR enzyme. Therefore, synthesized FA sulfonamide conjugates were docked in *Staphylococcus aureus* DHFR enzyme active sites to determine the plausible binding modes of the novel synthesized compounds. The predicted glide scores of the synthesized compounds are in the range from -4.7 to -7.7 kcal mol $^{-1}$, as given in Table 4. Fig. 1 shows that the best active compound binds well at the active site of the DHFR enzyme. The best binding pose of the **DS2** compound is reasonably well superimposed on the cocrystal ligand (trimethoprim) as shown in Fig. 1a. The head part phenyl ring of the **DS2** structure in the synthesized inhibitor series is in the same position as the trimethoprim head group.⁵⁰ The **DS2** also forms hydrogen bonding with the backbone carbonyl of Leu-20 as shown in Fig. 1b, and the residues point towards the solvent exposed site. Similarly, the Phe-92 residue forms π - π stacking with the head part phenyl ring of the **DS2** compound in the binding site. The interatomic calculated distances of the **DS2** compound atoms and the side chain atoms of the DHFR enzyme did not result in any bad clashes, which explain that the predicted binding pose can be accepted as the true binding mode. We have also observed in docking studies that the best docked pose of some of the novel synthesized compounds flipped their orientation in comparison to the co-crystal ligand. This might be due to the coupling of large moieties with the amino group of the pteridine ring present in the folic acid. In many compounds, the docking scores agreed well with the observed biological activities of the synthesized compounds,

however those that did not exhibit correlation could be preferentially binding partially or fully at the NADPH substrate binding site.

4. Conclusion

In this study, folic acid sulfonamide conjugates were synthesized successfully and their structures were confirmed using FTIR, and ^1H and ^{13}C NMR spectroscopies. The combination of **DS2** with ampicillin enhanced their antimicrobial activities compared to their individual use. Moreover, the FIC index was less than or equal to 1, which indicated that the combination system had a good additive effect. The majority of the conjugates have shown a similar or higher binding affinity with the DHFR enzyme as compared to the standard drug and thus can be used to design better antimicrobial agents. Further molecular docking studies demonstrated that the synthesized compounds are binding at the trimethoprim active site in the DHFR enzyme, which could help researchers to design more active molecules.

Conflicts of interest

We wish to confirm that there are no known conflicts of interest associated with this publication.

Acknowledgements

The authors are thankful to HEC-Pakistan for providing financial support to purchase the software and hardware for the computational studies vide Projects No. 6804/Federal/NRPU/R&D/HEC/2016 & 8094/Balochistan/NRPU/R&D/HEC/2017.

References

- G. Nitulescu, I. M. Nicorescu, O. T. Oлару, A. Ungurianu, D. P. Mihai, A. Zanfirescu, G. M. Nitulescu and D. Margina, *Int. J. Mol. Sci.*, 2017, **18**, 2217.



- 2 M. V. Raimondi, O. Randazzo, M. La Franca, G. Barone, E. Vignoni, D. Rossi and S. Collina, *Molecules*, 2019, **24**, 1140.
- 3 A. Singh, N. Deshpande, N. Pramanik, S. Jhunjhunwala, A. Rangarajan and H. S. Atreya, *Sci. Rep.*, 2018, **8**, 3190.
- 4 N. Wang, J.-X. Ren and Y. Xie, *J. Biomol. Struct. Dyn.*, 2019, **37**, 1054–1061.
- 5 M. A. Qadir, M. Ahmed and M. Iqbal, *BioMed Res. Int.*, 2015, **2015**, 7.
- 6 M. A. Qadir, M. Ahmed and A. Khaleeq, *Lat. Am. J. Pharm.*, 2015, **34**, 719–724.
- 7 M. A. Qadir, M. Ahmed, H. Aslam, S. Waseem and M. I. Shafiq, *J. Chem.*, 2015, **2015**, 8.
- 8 M. A. Qadir, M. Ahmed, M. I. Shafiq, N. Mahmood, S. Anwar, T. Habib and S. Nosheen, *Lat. Am. J. Pharm.*, 2015, **34**, 1511–1515.
- 9 A. Tačić, V. Nikolić, L. Nikolić and I. Savić, *Advanced technologies*, 2017, **6**, 58–71.
- 10 D. Diaconu, V. Mangalagiu, D. Amariuca-Mantu, V. Antoci, C. L. Giuroiu and I. I. Mangalagiu, *Molecules*, 2020, **25**, 2946.
- 11 Y.-Y. Hu, R. R. Yadav Bheemanaboina, N. Battini and C.-H. Zhou, *Mol. Pharm.*, 2019, **16**, 1036–1052.
- 12 M. F. Hussein, *Mediterr. J. Chem.*, 2018, **7**, 370–385.
- 13 J. Mareddy, S. B. Nallapati, J. Anireddy, Y. P. Devi, L. N. Mangamoori, R. Kapavarapu and S. Pal, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 6721–6727.
- 14 L. Chen, D. Yang, Z. Pan, L. Lai, J. Liu, B. Fang and S. Shi, *Chem. Biol. Drug Des.*, 2015, **86**, 239–245.
- 15 J. Mareddy, N. Suresh, C. G. Kumar, R. Kapavarapu, A. Jayasree and S. Pal, *Bioorg. Med. Chem. Lett.*, 2017, **27**, 518–523.
- 16 J. Liu, C. Liu, X. Zhang, L. Yu, X. Gong and P. Wang, *J. Enzyme Inhib. Med. Chem.*, 2019, **34**, 1380–1387.
- 17 S. D. Firke and S. B. Bari, *Bioorg. Med. Chem.*, 2015, **23**, 5273–5281.
- 18 A. Abbas, S. Murtaza, M. N. Tahir, S. Shamim, M. Sirajuddin, U. A. Rana, K. Naseem and H. Rafique, *J. Mol. Struct.*, 2016, **1117**, 269–275.
- 19 N. U. H. Khan, S. Zaib, K. Sultana, I. Khan, B. Mougang-Soume, H. Nadeem, M. Hassan and J. Iqbal, *RSC Adv.*, 2015, **5**, 30125–30132.
- 20 S. Mutahir, J. Jończyk, M. Bajda, I. U. Khan, M. A. Khan, N. Ullah, M. Ashraf, S. Riaz, S. Hussain and M. Yar, *Bioorg. Chem.*, 2016, **64**, 13–20.
- 21 M. Ahmed, M. A. Qadir, M. I. Shafiq, M. Muddassar, Z. Q. Samra and A. Hameed, *Arabian J. Chem.*, 2019, **12**, 41–53.
- 22 M. Ahmed, M. A. Qadir, A. Hameed, M. N. Arshad, A. M. Asiri and M. Muddassar, *Biochem. Biophys. Res. Commun.*, 2017, **490**, 434–440.
- 23 M. Ahmed, M. A. Qadir, A. Hameed, M. N. Arshad, A. M. Asiri and M. Muddassar, *Bioorg. Chem.*, 2018, **76**, 218–227.
- 24 R. A. Azzam, R. E. Elsayed and G. H. Elgemeie, *ACS Omega*, 2020, **5**, 10401–10414.
- 25 C. Capasso and C. T. Supuran, *Bacterial Resistance to Antibiotics—From Molecules to Man*, 2019, pp. 163–172.
- 26 N. A. Al-Masoudi and Y. A. Al-Soud, *Nucleosides, Nucleotides Nucleic Acids*, 2008, **27**, 1034–1044.
- 27 J. N. Domínguez, C. León, J. Rodrigues, N. G. de Domínguez, J. Gut and P. J. Rosenthal, *Il Farmaco*, 2005, **60**, 307–311.
- 28 Y. Ding, K. L. Smith, V. Prasad, V. Chamakura and B. Wang, *Lett. Org. Chem.*, 2018, **15**, 87–91.
- 29 I. Ugwu David, C. Okoro Uchechukwu and D. Chukwurah Thompson, *Med. Chem.*, 2014, **4**, 357–360.
- 30 L. Novotny, P. Rauko and H. Schott, *Anticancer Res.*, 2010, **30**, 4891–4898.
- 31 A. Thiry, J.-M. Dogne, C. T. Supuran and B. Masereel, *Curr. Pharm. Des.*, 2008, **14**, 661–671.
- 32 P. Selvam, N. Murugesu, M. Chandramohan, Z. Debyser and M. Witvrouw, *Indian J. Pharm. Sci.*, 2008, **70**, 779.
- 33 A. T. Hopper, A. Brockman, A. Wise, J. Gould, J. Barks, J. B. Radke, L. D. Sibley, Y. Zou and S. Thomas, *J. Med. Chem.*, 2019, **62**, 1562–1576.
- 34 A. Wróbel, K. Arciszewska, D. Maliszewski and D. Drozdowska, *J. Antibiot.*, 2020, **73**, 5–27.
- 35 D. Fernández-Villa, M. R. Aguilar and L. Rojo, *Int. J. Mol. Sci.*, 2019, **20**, 4996.
- 36 Y. Zhao, W. R. Shadrick, M. J. Wallace, Y. Wu, E. C. Griffith, J. Qi, M.-K. Yun, S. W. White and R. E. Lee, *Bioorg. Med. Chem. Lett.*, 2016, **26**, 3950–3954.
- 37 M. Tyers and G. D. Wright, *Nat. Rev. Microbiol.*, 2019, **17**, 141–155.
- 38 R. Capela, R. Moreira and F. Lopes, *Int. J. Mol. Sci.*, 2019, **20**, 5748.
- 39 X. Deng and N. S. Mani, *Green Chem.*, 2006, **8**, 835–838.
- 40 R. A. Nadeem, M. Abdul Qadir, M. Ahmed and I. Sajid, *Lett. Drug Des. Discovery*, 2020, **17**, 264–270.
- 41 M. Ahmed, M. A. Qadir and M. I. Shafiq, *Lat. Am. J. Pharm.*, 2017, **36**, 1789–1795.
- 42 O. O. Olajuyigbe and A. J. Afolayan, *Int. J. Mol. Sci.*, 2012, **13**, 8915–8932.
- 43 M. Cammarata, R. Thyer, M. Lombardo, A. Anderson, D. Wright, A. Ellington and J. S. Brodbelt, *Chem. Sci.*, 2017, **8**, 4062–4072.
- 44 M. R. Sawaya and J. Kraut, *Biochemistry*, 1997, **36**, 586–603.
- 45 B. R. Bhawana, H. S. Buttar, V. Jain and N. Jain, *J. Agric. Food Chem.*, 2011, **59**, 2056–2061.
- 46 X.-M. Wang, J. Xu, Y.-P. Li, H. Li, C.-S. Jiang, G.-D. Yang, S.-M. Lu and S.-Q. Zhang, *Eur. J. Med. Chem.*, 2013, **67**, 243–251.
- 47 J. Lehár, A. S. Krueger, W. Avery, A. M. Heilbut, L. M. Johansen, E. R. Price, R. J. Rickles, G. F. Short Iii, J. E. Staunton and X. Jin, *Nat. Biotechnol.*, 2009, **27**, 659–666.
- 48 X. Li, G. Qin, Q. Yang, L. Chen and L. Xie, *BioMed Res. Int.*, 2016, **2016**, 8518945.
- 49 C. Zhang and G. Yan, *Synth. Syst. Biotechnol.*, 2019, **4**, 67–72.
- 50 T. Khamkhenshornphanuch, K. Kulkraisri, A. Janjamratsaeng, N. Plabutong, A. Thammahong, K. Manadee, S. Na Pombejra and T. Khotavivattana, *Molecules*, 2020, **25**, 3059.

